Uncategorized
Eyenovia Publication of EYE 102 Phase II Results Demonstrates Strong Pharmacodynamic Effect, Tolerability and Reduced Systemic Exposure of High-Precision Micro-dosing compared to Conventional Eyedroppers
NEW YORK--(BUSINESS WIRE)--Eyenovia Inc., a clinical-stage ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of potential first-in-class micro-therapeutics for the eye, today announced that the positive results of its EYE 102 Phase II study have been published online ahead of print in the peer-reviewed journal Therapeutic Delivery. The top-line results from this study, showing that the study met its primary endpoints, were first announced in a press